The Board of Directors of the Company, at its meeting held today, i.e. on Thursday, 13 November 2025, has inter alia, considered and approved the unaudited (Standalone and Consolidated) ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.6 pts less than Nifty Microcap 250 and 6.5 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Star Imaging and Path Lab Ltd approved unaudited financial results for the half year ended September 30, 2025, along with a clean (unmodified) limited review report from statutory auditor BHS & Co. Revenue from operations rose sharply to Rs 4,524 lakhs from Rs 2,592 lakhs in the same period last year, a jump of roughly 74%. Profit after tax grew about 62% to Rs 1,003 lakhs versus Rs 620 lakhs, with EPS of Rs 5.79 for the half year. However, EBITDA margin (PBT + depreciation + finance costs) compressed to about 39% from around 45% a year ago, as total expenses grew faster than revenue. The balance sheet strengthened materially post-IPO, with reserves jumping to Rs 8,939 lakhs from Rs 3,356 lakhs and long-term borrowings cut by more than half. Operating cash flow turned positive at Rs 460 lakhs versus a negative Rs 588 lakhs in FY25.
Strong top-line and bottom-line growth signal robust business expansion for this recently-listed diagnostics chain, which should be viewed positively by shareholders. Watch-out is the declining margin trend and rising trade receivables, which could pressure working capital. The IPO proceeds have significantly strengthened the balance sheet and funded full loan repayment.